恩替卡韦治疗HBeAg阴性慢性乙型肝炎患者的依从性调查

陶军秀; 李晓东; 曹婷; 肖明中; 吴辉坤; 吴登; 任朦; 汪婷; 白丽英

doi:10.3969/j.issn.1001-5256.2017.08.030

恩替卡韦治疗HBeAg阴性慢性乙型肝炎患者的依从性调查

DOI: 10.3969/j.issn.1001-5256.2017.08.030

1. 湖北省中医院肝病科
2. 湖北省中医药研究院

基金项目:

国家中医临床研究基地业务建设科研专项课题(JDZX2012051)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1254
- HTML全文浏览量: 13
- PDF下载量: 342
- 被引次数: 0
出版历程
- 出版日期: 2017-08-20

A study of compliance in patients with HBeAg-negative chronic hepatitis B receiving entecavir treatment

Department of Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine

Research funding:

摘要

摘要: <正>慢性乙型肝炎(CHB)是我国的常见病,由于HBV复制模板cccDNA半衰期较长,现有的抗病毒药物难以将其从体内彻底清除,故导致停药后复发率较高[1]。临床上经常出现患者漏服药物或自行停药、自行延长服药间隔时间等情况,为提高患者对疾病的知晓率、对疾病慢性发展过程的重视程度,更好
- 肝炎,乙型,慢性 /
- 肝炎e抗原,乙型 /
- 治疗 /
- 恩替卡韦 /
- 病人依从
- hepatitis B, chronic /
- hepatitis B e antigens /
- therapy /
- entecavir /
- patient compliance

HTML全文

参考文献(11)

[1]Expert Committee on Antiviral Therapy for Chronic Hepatitis B Patients Treated with Nucleos (t) ide Analogues.Expert consensus on antiviral therapy for chronic hepatitis B patients treated with nucleos (t) ide analogues[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2013, 7 (1) :145-149. (in Chinese) 慢性乙型肝炎核苷 (酸) 类药物经治患者抗病毒治疗专家委员会.慢性乙型肝炎核苷 (酸) 类药物经治患者抗病毒治疗专家共识[J/CD].中华实验和临床感染病杂志:电子版, 2013, 7 (1) :145-149.

[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[3]Experts attending the discussion on long-treatment of chronic hepatitis B.Long-term treatment of chronic hepatitis B[J].J Clin Hepatol, 2014, 30 (11) :1099-1105. (in Chinese) 慢性乙型肝炎长期治疗讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的长期性[J].临床肝胆病杂志, 2014, 30 (11) :1099-1105.

[4]MARCELLIN P, ASSELAH T.Long-term therapy for chronic hepatitis B:hepatitis B virus DNA suppression leading to cirrhosis reversal[J].J Gastroenterol Hepatol, 2013, 28 (6) :912-923.

[5]WANG JB, KANG HY, CAO XZ, et al.The effect of LAM or ADV add-on therapy for HBe Ag negative chronic hepatitis B patients with suboptimal response to PEG-IFN[J].Int J Virol, 2015, 22 (5) :310-314. (in Chinese) 王建彬, 康海燕, 曹雪政, 等.聚乙二醇干扰素应答不佳HBe Ag阴性慢性乙肝患者加用拉米夫定或阿德福韦酯疗效观察[J].国际病毒学杂志, 2015, 22 (5) :310-314.

[6]CHEN HM, SHAO GH.Criteria for withdrawal of nucleos (t) ide analogues and their clinical significance in treatment of chronic hepatitis B[J].J Clin Hepatol, 2016, 32 (7) :1283-1286. (in Chinese) 陈合民, 邵国辉.核苷和核苷酸类药物治疗慢性乙型肝炎停药标准的探讨[J].临床肝胆病杂志, 2016, 32 (7) :1283-1286.

[7]DONG N, HE B, ZHUANG H.An online questionnaire survey on awareness of antiviral treatment in patients with chronic hepatitis B[J].Chin Hepatol, 2009, 14 (1) :8-10. (in Chinese) 董南, 何波, 庄辉.慢性乙型肝炎患者对疾病和抗病毒治疗的认知程度调查[J].肝脏, 2009, 14 (1) :8-10.

[8]TAO JX, LI XD, GAO XL, et al.Application of multimode follow-up health management model in multi-center clinical trials on chronic liver diseases[J].Chin J Integr Tradit West Med Liver Dis, 2016, 26 (6) :371-373. (in Chinese) 陶军秀, 李晓东, 高小连, 等.多方式随访健康管理模式在慢性肝病多中心临床研究中的应用[J].中西医结合肝病杂志, 2016, 26 (6) :371-373.

[9]ZHANG H, CHAO JQ, ZHU LG, et al.Outpatient direct costs of viral hepatitis B patients and its influencing factors[J].Chin Gen Pract, 2014, 17 (11) :1293-1296. (in Chinese) 张华, 巢健茜, 朱立国, 等.乙型病毒性肝炎患者门诊直接经济负担及影响因素调查[J].中国全科医学, 2014, 17 (11) :1293-1296.

[10]CHOTIYAPUTTA W, PETERSON C, DITAH FA, et al.Persistence and adherence to nucleos (t) ide analogue treatment for chronic hepatitis B[J].J Hepatol, 2011, 54 (1) :12-18.

[11]HA NB, HA NB, GARCIA RT, et al.Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B[J].Dig Dis Sci, 2011, 56 (8) :2423-2431.

施引文献

资源附件(0)

访问统计